BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
Subscribe To Our Newsletter & Stay Updated
